RT Journal Article
SR Electronic
T1 Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 718
OP 722
DO 10.1136/ard.61.8.718
VO 61
IS 8
A1 Buttgereit, F
A1 Da Silva, J A P
A1 Boers, M
A1 Burmester, G-R
A1 Cutolo, M
A1 Jacobs, J
A1 Kirwan, J
A1 Köhler, L
A1 van Riel, P
A1 Vischer, T
A1 Bijlsma, J W J
YR 2002
UL http://ard.bmj.com/content/61/8/718.abstract
AB In rheumatology and other medical specialties there is a discrepancy between the widespread use and the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of glucocorticoid treatment regimens used in various phases of diseases vary between countries and institutions. Given this background, a workshop under the auspices of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials was held to discuss this issue and to seek a consensus on nomenclature for glucocorticoid treatment. This report summarises the panel's discussion and recognises that answers derived from consensus conferences are not definitive. Nevertheless, recommendations on glucocorticoid treatment are presented that (1) reflect current and best knowledge available and (2) take into account current clinical practice. A question-answer rationale presentation style has been chosen to convey the messages, to summarise the meeting in a readable format, and to avoid dogmatism.